RETRACTED ARTICLE: Involvement of the glutamate/glutamine cycle and glutamate transporter GLT-1 in antidepressant-like effects of Xiao Yao san on chronically stressed mice

Xiu Fang Ding1, Yue Hua Li2, Jiaxu Chen1, Long Ji Sun1, Haiyan Jiao1, Xin Xin Wang3, Yan Zhou1
1School of Basic Medical Science, Beijing University of Chinese Medicine, Beijing 100029, China
2Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100043, China
3School of Basic Medicine, Henan University of TCM, Henan, 450046, Henan, China

Tóm tắt

Abstract Background

Xiao Yao San (XYS) is an herbal prescription which is used in the treatment of depression for thousands of years from Song dynasty in China (960–1127 A.D.), and is the bestselling and most popular herb formula for treating major depression. This study aimed to assess the chronic antidepressant effects of XYS and fluoxetine in depressed mice induced by chronic unpredictable mild stress (CUMS) and its association with  alterations in glutamate/glutamine cycle and glutamate transporters.

Methods

Mice in the control and model group were given 0.5 ml physiological saline by intragastric administration. Mice in two treatment groups were given XYS (0.25 g/kg/d) and fluoxetine (2.6 mg/kg/d), respectively. The depressive-like behaviors such as forced swim test (FST), sucrose preference test (SPT) and novelty-suppressed feeding (NSF) test were measured after mice exposed to CUMS for 21 days. Body weight, contents of glutamate and glutamine, glutamine/glutamate ratio that is usually thought to reflect glutamate/glutamine cycle, and the protein and mRNA expressions of glutamate transporters (excitatory amino acid transporter 1–2,GLAST/EAAT1 and GLT-1/EAAT2) were measured. The immunoreactivities of GLAST and GLT-1 in the hippocampus were also investigated.

Results

After CUMS exposure, mice exhibited depressive-like behaviors, body weight loss, increased glutamate level, decreased glutamine level, elevated glutamine/glutamate ratio, decreased GLT-1 protein expression and mRNA level, and decreased average optical density (AOD) of GLT-1 in the CA1, CA3 and DG in the hippocampus. These abnormalities could be effectively reversed by XYS or fluoxetine treatment. In addition, the study also found that GLAST expression in the hippocampus could not be altered by 21-d CUMS.

Conclusion

The studies indicated that XYS may have therapeutic actions on depression-like behaviors induced by CUMS in mice possibly mediated by modulation of glutamate/glutamine cycle and glutamate transporter GLT-1 in the hippocampus.

Từ khóa


Tài liệu tham khảo

Mathers C, Fat DM, Boerma J. The global burden of disease: 2004 update: World Health Organization; 2008.

American PA. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®): American psychiatric pub; 2013.

Denollet J, Maas K, Knottnerus A, Keyzer JJ, Pop VJ. Anxiety predicted premature all-cause and cardiovascular death in a 10-year follow-up of middle-aged women. J Clin Epidemiol. 2009;62:452–6.

Verhoof E, Maurice-Stam H, Heymans H, Grootenhuis M. Health-related quality of life, anxiety and depression in young adults with disability benefits due to childhood-onset somatic conditions. Child and adolescent psychiatry and mental health. 2013;7:12–21.

Lépine J, Briley M. The increasing burden of depression. Neuropsych Dis Treat. 2011;7:3.

O Leary OF, Dinan TG, Cryan JF: Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol 2015, 753:32–50.

Zheng G, Li R, Shi H, Xiao Q, Xu W, Wang Y, Lu C, Lu A: Exploring the potential therapeutic mechanism of Xiao-Yao-San for major depression. In; 2014–01-01. IEEE; 2014: 229–234.

Jing LL, Zhu XX, Lv ZP, Sun XG. Effect of Xiaoyaosan on major depressive disorder. Chin Med. 2015;10:18.

Butler L, Pilkington K. Chinese herbal medicine and depression: the research evidence. Evid Based Complement Alternat Med. 2013;2013:739716.

Zhu X, Xia O, Han W, Shao M, Jing L, Fan Q, et al. Xiao Yao san improves depressive-like behavior in rats through modulation of β -Arrestin 2-mediated pathways in hippocampus. Evid-based Compl Alt. 2014;2014

Ding XF, Zhao XH, Tao Y, Zhong WC, Fan Q, Diao JX, et al. Xiao Yao san improves depressive-like behaviors in rats with chronic immobilization stress through modulation of locus Coeruleus-norepinephrine system. Evid Based Complement Alternat Med. 2014;2014:605914.

Valentine GW, Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol. 2009;78:431–9.

Shan D, Lucas EK, Drummond JB, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia. Schizophr Res. 2013;144:1–8.

Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675–86.

Beart PM, O'Shea RD. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Brit J Pharmacol. 2007;150:5–17.

Bunch L, Erichsen MN, Jensen AA: Excitatory amino acid transporters as potential drug targets. 2009.

Chandley MJ, Szebeni K, Szebeni A, Crawford J, Stockmeier CA, Turecki G, et al. Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder. J Psychiatry Neurosci. 2013;38:276–84.

Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology. 2010;58:465–73.

Wang SX, Chen JX, Yue GX, Bai MH, Kou MJ, Jing ZY. Xiaoyaosan decoction regulates changes in neuropeptide y and leptin receptor in the rat arcuate nucleus after chronic immobilization stress. Evidence - Based Complementary and Alternative Medic. 2012;2012

Liu YY, Guo XL, Zhao HB, Zhang YF, Ll J, Chen JX. Behavior evaluation of rat model with stagnation of liver qi and spleen deficiency syndrome regulating by Xiaoyao san extract. China Journal of Traditional Chinese Medicine and Pharmacy. 2013;7:062.

Booth B, Arnold ME, DeSilva B, Amaravadi L, Dudal S, Fluhler E, Gorovits B, Haidar SH, Kadavil J, Lowes S: Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The. Revised FDA guidance. AAPS J. 2013;2015(17):277–288.

Li P, Tang XD, Cai ZX, Qiu JJ, Lin XL, Zhu T, et al. CNP signal pathway up-regulated in rectum of depressed rats and the interventional effect of Xiaoyaosan. World J Gastroenterol. 2015;21:1518–30.

Ding L, Zhang X, Guo H, Yuan J, Li S, Hu W, et al. The functional study of a Chinese herbal compounded antidepressant medicine - Jie Yu Chu fan capsule on chronic unpredictable mild stress mouse model. PLoS One. 2015;10:e133405.

Cao X, Li LP, Wang Q, Wu Q, Hu HH, Zhang M, et al. Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med. 2013;19:773–7.

Tang J, Xue W, Xia B, Ren L, Tao W, Chen C, et al. Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice. Sci Rep-UK. 2015;5

Lijima M, Fukumoto K, Chaki S. Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. Behav Brain Res. 2012;235:287–92.

Lopes RP, Reyes RC, Romero-González R, Frenich AG, Vidal JLM. Development and validation of a multiclass method for the determination of veterinary drug residues in chicken by ultra high performance liquid chromatography–tandem mass spectrometry. Talanta. 2012;89:201–8.

Pothion S, Bizot J, Trovero F, Belzung C. Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav Brain Res. 2004;155:135–46.

Tang ZJ, Zou W, Yuan J, Zhang P, Tian Y, Xiao ZF, et al. Antidepressant-like and anxiolytic-like effects of hydrogen sulfide in streptozotocin-induced diabetic rats through inhibition of hippocampal oxidative stress. Behav Pharmacol. 2015;26:427–35.

Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009;195:202–10.

Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD: The mouse forced swim test. J Vis Exp 2012:e3638.

Fawcett J, Clark DC, Scheftner WA, Gibbons RD. Assessing anhedonia in psychiatric patients: the pleasure scale. Arch Gen Psychiatry. 1983;40:79–84.

Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Tar. 2014;18:1049–63.

Nishi D, Hashimoto K, Noguchi H, Hamazaki K, Hamazaki T, Matsuoka Y. Glutamatergic system abnormalities in posttraumatic stress disorder. Psychopharmacology. 2015:1–8.

Kucukibrahimoglu E, Saygin MZ, Caliskan M, Kaplan OK, Unsal C, Goren MZ. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol. 2009;65:571–7.

Merkl A, Schubert F, Quante A, Luborzewski A, Brakemeier E, Grimm S, et al. Abnormal cingulate and prefrontal cortical neurochemistry in major depression after electroconvulsive therapy. Biol Psychiatry. 2011;69:772–9.

Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:1155–8.

Yildiz-Yesiloglu A, Ankerst DP. Review of 1 H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res Neuroimaging. 2006;147:1–25.

Ajilore O, Haroon E, Kumaran S, Darwin C, Binesh N, Mintz J, et al. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology. 2007;32:1224–31.

Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193–200.

Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000;47:586–93.

Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CJ, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30:1155–8.

Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000;47:305–13.

Mannie ZN, Filippini N, Williams C, Near J, Mackay CE, Cowen PJ. Structural and functional imaging of the hippocampus in young people at familial risk of depression. Psychol Med. 2014;44:2939–48.

Lee Y, Son H, Kim G, Kim S, Lee DH, Roh GS, et al. Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice. Journal of psychiatry & neuroscience: JPN. 2013;38:183.

Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–7.

Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci. 2005;102:15653–8.

Mayhew J, Beart PM, Walker FR. Astrocyte and microglial control of glutamatergic Signalling: a primer on understanding the disruptive role of chronic stress. J Neuroendocrinol. 2015;27

Zschocke J, Bayatti N, Clement AM, Witan H, Figiel M, Engele J, et al. Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions. J Biol Chem. 2005;280:34924–32.

Reagan LP, Rosell DR, Wood GE, Spedding M, Muñoz C, Rothstein J, et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. P Natl Acad Sci Usa. 2004;101:2179–84.

Fontella FU, Vendite DA, Tabajara AS, Porciúncula LO, Da Silva Torres IL, Jardim FM, et al. Repeated restraint stress alters hippocampal glutamate uptake and release in the rat. Neurochem Res. 2004;29:1703–9.

Suo L, Zhao L, Si J, Liu J, Zhu W, Chai B, et al. Predictable chronic mild stress in adolescence increases resilience in adulthood. Neuropsychopharmacology. 2013;38:1387–400.

Parihar VK, Hattiangady B, Kuruba R, Shuai B, Shetty AK. Predictable chronic mild stress improves mood, hippocampal neurogenesis and memory. Mol Psychiatry. 2011;16:171–83.

Chen JX, Yao LH, Xu BB, Qian K, Wang HL, Liu ZC, Wang X, Wang G: Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress. Journal of Huazhong University of Science and Technology. Medical sciences= Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban= Huazhong keji daxue xuebao. Yixue Yingdewen ban 2014, 34:838–844.

Miguel-Hidalgo JJ, Waltzer R, Whittom AA, Austin MC, Rajkowska G, Stockmeier CA. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disorders. 2010;127:230–40.

Raudensky J, Yamamoto BK. Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function. Brain Res. 2007;1135:129–35.